C12N 2310/314
Phosphoramidates
C12N2310/314 (Phosphoramidates) appears on 429 US grants and 725 published applications in this corpus.
Search patents in C12N- Granted patents
- 429
- Published applications
- 725
- Assignees
- 209
- Inventors
- 924
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 6 | 0 |
| 1998 | 7 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 6 | 2 |
| 2002 | 6 | 3 |
| 2003 | 2 | 16 |
| 2004 | 10 | 12 |
| 2005 | 3 | 11 |
| 2006 | 3 | 8 |
| 2007 | 1 | 15 |
| 2008 | 6 | 6 |
| 2009 | 9 | 15 |
| 2010 | 9 | 10 |
| 2011 | 12 | 14 |
| 2012 | 11 | 25 |
| 2013 | 13 | 29 |
| 2014 | 13 | 29 |
| 2015 | 31 | 49 |
| 2016 | 28 | 39 |
| 2017 | 28 | 37 |
| 2018 | 29 | 36 |
| 2019 | 28 | 48 |
| 2020 | 33 | 36 |
| 2021 | 31 | 45 |
| 2022 | 19 | 44 |
| 2023 | 16 | 61 |
| 2024 | 23 | 42 |
| 2025 | 21 | 58 |
| 2026 | 15 | 35 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Compounds and methods for reducing PLN expression22 Sep 2026US 12,742,170 B2Ionis Pharmaceuticals, Inc.
- Endosomal cleavable linkers15 Sep 2026US 12,735,702 B2Alnylam Pharmaceuticals, Inc.
- RNA-editing oligonucleotides and uses thereof30 Jun 2026US 12,668,801 B2Korro Bio, Inc.
- Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping9 Jun 2026US 12,648,998 B1Avidity Biosciences, Inc.
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same1 Oct 2026US 2026/0297581 A1Aligos Therapeutics, Inc.
- Modified iscb nucleases, modified guide rnas, and uses thereof24 Sep 2026US 2026/0286324 A1Aera Therapeutics, Inc.
- Antisense RNA (asRNA) Technology and Use Thereof24 Sep 2026US 2026/0286353 A11Globe Health Institute LLC
- Chemically modified antisense oligonucleotides for use in rna editing17 Sep 2026US 2026/0275338 A1ProQR Therapeutics II B.V.
Most cited
By later US patents
- Inhibition of cell proliferation using antisense oligonucleotides753US 5,756,476 AThe United States of America as represented by the Department of Health and Human Services · 1998
- Oligoribonucleotides and ribonucleases for cleaving RNA486US 6,107,094 AIsis Pharmaceuticals, Inc. · 2000
- Method of site-specific alteration of RNA and production of encoded polypeptides431US 5,149,797 AWorcester Foundation for Experimental Biology · 1992
- Method of site-specific alteration of RNA and production of encoded polypeptides421US 5,366,878 AWorcester Foundation for Experimental Biology · 1994
- Oligoribonucleotides for cleaving RNA385US 5,898,031 AIsis Pharmaceuticals, Inc. · 1999